Mixed adenoneuroendocrine carcinoma of the distal bile duct: a case report.
Immunohistochemistry
Mixed adenoneuroendocrine carcinoma
Neuroendocrine neoplasm
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
06 Jul 2020
06 Jul 2020
Historique:
received:
21
05
2020
accepted:
22
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
8
7
2020
Statut:
epublish
Résumé
Mixed adenoneuroendocrine carcinoma (MANEC) of the common bile duct (CBD) is very rare, with only 10 reported cases. Here, we report a case of MANEC of the distal bile duct (DBD) that was surgically resected under a diagnosis of cholangiocarcinoma (CCA). A 60-year-old male had epigastric pain and was admitted to our hospital for the treatment of a suspected CBD stone. Upon admission, laboratory findings revealed elevated hepatobiliary enzymes including serum aspartate aminotransferase, serum alanine aminotransferase, serum glutamyltransferase, and serum alkaline phosphatase. Both carcinoembryonic antigen and carbohydrate antigen 19-9 were negative. Computed tomography (CT) showed dilation of the CBD. Endoscopic retrograde cholangiopancreatography (ERCP) showed circumferential stenosis and a 5-mm elevated lesion in the DBD. Brush cytology showed atypical ductal cells, indicating adenocarcinoma (AC) of the DBD. Under a diagnosis of CCA of the DBD, a subtotal stomach-preserving pancreaticoduodenectomy was performed. Neither peritoneal dissemination nor lymph node metastasis was found. Microscopically, the lesion was seen to be composed of predominantly well-differentiated tubular AC in the superficial layer of the tumor, admixed with neuroendocrine carcinoma (NEC) in the deeper portion, indicating a diagnosis of MANEC of the DBD. After immunohistochemical staining, NEC components were positive for synaptophysin and CD56 and were for SSTR2, SSTR5, and mammalian target of rapamycin (mTOR). Three months postsurgery, postoperative adjuvant chemotherapy with S-1 was started. More than 3 years postsurgery, he is alive without recurrence. MANEC is highly malignant, progresses rapidly, and has a poor prognosis. Preoperative diagnosis is difficult; therefore, identifying NEC components by immunohistochemical staining using resected specimens is important.
Sections du résumé
BACKGROUND
BACKGROUND
Mixed adenoneuroendocrine carcinoma (MANEC) of the common bile duct (CBD) is very rare, with only 10 reported cases. Here, we report a case of MANEC of the distal bile duct (DBD) that was surgically resected under a diagnosis of cholangiocarcinoma (CCA).
CASE PRESENTATION
METHODS
A 60-year-old male had epigastric pain and was admitted to our hospital for the treatment of a suspected CBD stone. Upon admission, laboratory findings revealed elevated hepatobiliary enzymes including serum aspartate aminotransferase, serum alanine aminotransferase, serum glutamyltransferase, and serum alkaline phosphatase. Both carcinoembryonic antigen and carbohydrate antigen 19-9 were negative. Computed tomography (CT) showed dilation of the CBD. Endoscopic retrograde cholangiopancreatography (ERCP) showed circumferential stenosis and a 5-mm elevated lesion in the DBD. Brush cytology showed atypical ductal cells, indicating adenocarcinoma (AC) of the DBD. Under a diagnosis of CCA of the DBD, a subtotal stomach-preserving pancreaticoduodenectomy was performed. Neither peritoneal dissemination nor lymph node metastasis was found. Microscopically, the lesion was seen to be composed of predominantly well-differentiated tubular AC in the superficial layer of the tumor, admixed with neuroendocrine carcinoma (NEC) in the deeper portion, indicating a diagnosis of MANEC of the DBD. After immunohistochemical staining, NEC components were positive for synaptophysin and CD56 and were for SSTR2, SSTR5, and mammalian target of rapamycin (mTOR). Three months postsurgery, postoperative adjuvant chemotherapy with S-1 was started. More than 3 years postsurgery, he is alive without recurrence.
CONCLUSIONS
CONCLUSIONS
MANEC is highly malignant, progresses rapidly, and has a poor prognosis. Preoperative diagnosis is difficult; therefore, identifying NEC components by immunohistochemical staining using resected specimens is important.
Identifiants
pubmed: 32632765
doi: 10.1186/s40792-020-00921-x
pii: 10.1186/s40792-020-00921-x
pmc: PMC7338298
doi:
Types de publication
Journal Article
Langues
eng
Pagination
160Références
World J Gastroenterol. 2013 May 28;19(20):3161-4
pubmed: 23716999
World J Gastroenterol. 2013 Jul 28;19(28):4616-23
pubmed: 23901240
Korean J Pathol. 2014 Dec;48(6):445-8
pubmed: 25588638
Onco Targets Ther. 2018 Apr 23;11:2295-2301
pubmed: 29731637
Cancers (Basel). 2012 Jan 16;4(1):11-30
pubmed: 24213223
J Int Med Res. 2019 Jul;47(7):3421-3426
pubmed: 31154920
World J Gastroenterol. 2014 Dec 21;20(47):18048-52
pubmed: 25548506
Am J Surg Pathol. 2012 Apr;36(4):601-11
pubmed: 22314183
Front Oncol. 2019 Feb 05;9:38
pubmed: 30805307
Surg Case Rep. 2016 Dec;2(1):141
pubmed: 27888490
APMIS. 2010 Aug;118(8):543-56
pubmed: 20666735
Surgery. 2016 Aug;160(2):525-6
pubmed: 26873297
Int J Surg Case Rep. 2017;39:43-50
pubmed: 28806619
Abdom Imaging. 2015 Jan;40(1):181-91
pubmed: 25008023
Int J Surg Case Rep. 2017;39:203-207
pubmed: 28854410
Dig Liver Dis. 2011 Dec;43(12):965-70
pubmed: 21856258
Pathol Oncol Res. 2014 Oct;20(4):765-75
pubmed: 24917351
J Gastroenterol Hepatol. 2017 Jan;32(1):11
pubmed: 28052461
JOP. 2013 Jan 10;14(1):71-3
pubmed: 23306338
Case Rep Pathol. 2014;2014:347949
pubmed: 24804133
Oncol Lett. 2019 Aug;18(2):1585-1596
pubmed: 31423226
Clin J Gastroenterol. 2011 Jun;4(3):174-178
pubmed: 26189350
Case Rep Gastrointest Med. 2016;2016:4827050
pubmed: 27375908
Virchows Arch. 2012 Mar;460(3):281-9
pubmed: 22358181
World J Gastroenterol. 2016 Aug 14;22(30):6960-4
pubmed: 27570432